JP6797833B2 - 効力検定 - Google Patents

効力検定 Download PDF

Info

Publication number
JP6797833B2
JP6797833B2 JP2017557438A JP2017557438A JP6797833B2 JP 6797833 B2 JP6797833 B2 JP 6797833B2 JP 2017557438 A JP2017557438 A JP 2017557438A JP 2017557438 A JP2017557438 A JP 2017557438A JP 6797833 B2 JP6797833 B2 JP 6797833B2
Authority
JP
Japan
Prior art keywords
cells
tgfβ1
mpc
medium
afc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017557438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517900A (ja
JP2018517900A5 (enExample
Inventor
ポール・シモンズ
コルビー・サイア
フィオナ・シー
Original Assignee
メゾブラスト・インターナショナル・エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901605A external-priority patent/AU2015901605A0/en
Application filed by メゾブラスト・インターナショナル・エスアーエールエル filed Critical メゾブラスト・インターナショナル・エスアーエールエル
Publication of JP2018517900A publication Critical patent/JP2018517900A/ja
Publication of JP2018517900A5 publication Critical patent/JP2018517900A5/ja
Priority to JP2020190850A priority Critical patent/JP7335222B2/ja
Application granted granted Critical
Publication of JP6797833B2 publication Critical patent/JP6797833B2/ja
Priority to JP2023132587A priority patent/JP7754893B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
JP2017557438A 2015-05-05 2016-05-04 効力検定 Active JP6797833B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020190850A JP7335222B2 (ja) 2015-05-05 2020-11-17 効力検定
JP2023132587A JP7754893B2 (ja) 2015-05-05 2023-08-16 効力検定

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901605 2015-05-05
AU2015901605A AU2015901605A0 (en) 2015-05-05 Potency assay
PCT/EP2016/060049 WO2016177805A1 (en) 2015-05-05 2016-05-04 Potency assay

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020190850A Division JP7335222B2 (ja) 2015-05-05 2020-11-17 効力検定

Publications (3)

Publication Number Publication Date
JP2018517900A JP2018517900A (ja) 2018-07-05
JP2018517900A5 JP2018517900A5 (enExample) 2019-06-06
JP6797833B2 true JP6797833B2 (ja) 2020-12-09

Family

ID=56087237

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017557438A Active JP6797833B2 (ja) 2015-05-05 2016-05-04 効力検定
JP2020190850A Active JP7335222B2 (ja) 2015-05-05 2020-11-17 効力検定
JP2023132587A Active JP7754893B2 (ja) 2015-05-05 2023-08-16 効力検定

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020190850A Active JP7335222B2 (ja) 2015-05-05 2020-11-17 効力検定
JP2023132587A Active JP7754893B2 (ja) 2015-05-05 2023-08-16 効力検定

Country Status (9)

Country Link
US (3) US11795435B2 (enExample)
EP (2) EP4015624B1 (enExample)
JP (3) JP6797833B2 (enExample)
KR (2) KR102582602B1 (enExample)
CN (2) CN107771220B (enExample)
AU (3) AU2016258980B2 (enExample)
CA (1) CA2984987C (enExample)
ES (2) ES2911266T3 (enExample)
WO (1) WO2016177805A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
KR102506822B1 (ko) * 2018-09-20 2023-03-06 시토스핀, 에스.엘. 기능적 중간엽 줄기 세포의 농축된 집단을 수득하는 방법, 이의 수득된 세포 및 이를 포함하는 조성물
WO2020141473A1 (en) * 2019-01-02 2020-07-09 Mesoblast International Sárl Method for treating lower back pain
US20230221303A1 (en) * 2020-04-20 2023-07-13 Longeveron Inc. Potency assay
EP4641205A1 (en) * 2022-12-23 2025-10-29 Kangstem Biotech Co., Ltd. Method for selecting stem cells with enhanced cartilage differentiation capability and cell therapy product comprising same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
AU680921B2 (en) 1993-05-17 1997-08-14 Regents Of The University Of California, The Ribozyme gene therapy for HIV infection and AIDS
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
CA2360044A1 (en) 1999-01-15 2000-07-20 Medtox Scientific, Inc. Lateral flow test strip
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
WO2001097872A1 (en) 2000-06-22 2001-12-27 Austin Sam L Bioadhesive compositions and methods of preparation and use
AU2002331408B2 (en) 2001-08-20 2008-05-08 Proteome Systems Ltd Diagnostic testing process and apparatus
AU2003302132B2 (en) 2002-11-21 2008-02-21 Inverness Medical Switzerland Gmbh Bodily fluid markers of tissue hypoxia
KR101617319B1 (ko) 2005-04-12 2016-05-02 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체 세포의 분리
KR100802011B1 (ko) 2005-08-10 2008-02-12 인하대학교 산학협력단 층분리배양법을 이용한 골수에서의 중간엽 줄기세포분리방법
JP2011196840A (ja) 2010-03-19 2011-10-06 Univ Of Tokyo 急性大動脈解離の検査方法
CN103857788A (zh) * 2011-10-11 2014-06-11 骨治疗公司 生长和分化因子8(gdf-8)的用途
EP2997047B1 (en) 2013-05-16 2021-04-28 Agency For Science, Technology And Research Heparan sulphates
KR20150016117A (ko) * 2013-07-30 2015-02-11 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
CN103990181B (zh) * 2014-05-26 2015-07-08 中国人民解放军第四军医大学 一种具有诱导活性微载体-细胞复合物的制备方法及其应用

Also Published As

Publication number Publication date
CA2984987C (en) 2023-10-10
KR102582602B1 (ko) 2023-09-25
AU2016258980A1 (en) 2017-11-23
JP7754893B2 (ja) 2025-10-15
EP3292199B1 (en) 2022-01-12
JP7335222B2 (ja) 2023-08-29
US20240409898A1 (en) 2024-12-12
BR112017023660A2 (pt) 2018-07-17
US20240076621A1 (en) 2024-03-07
KR20230140604A (ko) 2023-10-06
CA2984987A1 (en) 2016-11-10
WO2016177805A1 (en) 2016-11-10
JP2018517900A (ja) 2018-07-05
AU2022203140A1 (en) 2022-06-02
EP4015624B1 (en) 2025-02-19
JP2021036892A (ja) 2021-03-11
US20200140822A1 (en) 2020-05-07
EP4015624A1 (en) 2022-06-22
CN107771220B (zh) 2022-07-05
CN107771220A (zh) 2018-03-06
JP2023159260A (ja) 2023-10-31
HK1247236A1 (zh) 2018-09-21
AU2025205043A1 (en) 2025-07-24
EP3292199A1 (en) 2018-03-14
AU2016258980B2 (en) 2022-02-17
KR102885856B1 (ko) 2025-11-14
CN115141872A (zh) 2022-10-04
KR20180041621A (ko) 2018-04-24
ES2911266T3 (es) 2022-05-18
US11795435B2 (en) 2023-10-24
ES3018944T3 (en) 2025-05-19
AU2022203140B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
JP7754893B2 (ja) 効力検定
WO2004007697A2 (en) Methods of implanting mesenchymal stem cells for tissue repair and formation
US20220143097A1 (en) Method for treating lower back pain
Gay et al. Nose to back: Compatibility of nasal chondrocytes with environmental conditions mimicking a degenerated intervertebral disc
ES2676886T3 (es) Método para aumentar la función osteoblástica
HK1247236B (en) Potency assay
BR112017023660B1 (pt) Método para selecionar células precursoras de linhagem mesenquimal ou células-tronco humanas, composições e uso das mesmas
Taheem A Role for Hypoxia and Hypoxia Inducible Factor during Chondrogenesis of Bone Marrow Mesenchymal Stem Cells
Hofer Traumatized muscle-derived multipotent progenitor cells: Pro-angiogenic activity, promotion of nerve growth, and osteogenic differentiation
Stoddart et al. eCM Welcomes you to Davos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200721

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201019

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201118

R150 Certificate of patent or registration of utility model

Ref document number: 6797833

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250